CoChat

Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

BACKGROUND: mutations occur in more than 90% of PDAC tumors. Daraxonrasib (RMC-6236) is an oral RAS(ON) multiselective inhibitor that targets guanosine triphosphate-bound mutant and wild-type RAS. METHODS: -mutated PDAC. RESULTS: G12, G13, or Q61 mutations, 29% (95% CI, 15 to 46) had an objective response. The median duration of response was 8.2 months (95% CI, 3.8 to 8.8), with median values of 8.1 months for progression-free survival and 15.6 months for overall survival. CONCLUSIONS: -mutated PDAC; antitumor activity was also reported. (Funded by Revolution Medicines; RMC-6236-001 ClinicalTrials.gov number, NCT05379985.).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa2505783

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 1

  1. Ying H, Kimmelman AC, Bardeesy N, Kalluri R, Maitra A, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2025;39:36-63.39510840

Cited by

See all 122

Metadata

Authors
Wolpin, B. M., Park, W., Garrido-Laguna, I., Spira, A., Starodub, A., Sommerhalder, D., Punekar, S. R., Barve, M., Pelster, M., Herzberg, B., Azad, N. S., Hecht, J. R., Ou, S. H. I., Lin, T., Kar, S., Tao, L., Vora, R., Hegde, A., Aung, K., & Hong, D. S.
Affiliations
  • Dana-Farber Cancer Institute (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Huntsman Cancer Institute, University of Utah, Salt Lake City
  • NEXT Oncology Virgina, Virgina Cancer Specialists Research Institute, Fairfax
  • Christ Hospital (US)
  • NEXT Oncology, San Antonio, TX
  • NYU Langone Health (US)
  • Mary Crowley Cancer Research Center (US)
  • Sarah Cannon Research Institute, Nashville
  • Columbia University (US)
  • Sidney Kimmel Comprehensive Cancer Center (US)
  • University of California, Los Angeles (US)
  • University of California, Irvine (US)
  • Revolution Medicines (United States) (US)
  • Miami Cancer Institute, Miami
  • The University of Texas MD Anderson Cancer Center (US)
Venue
New England Journal of Medicine
Published
2026-05-07
Volume
394
Issue
18
Pages
1790-1802
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W7160408317
Cited by
90
References
35
Citations by year
2026: 89
FWCI
263.51
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Revolution Medicines
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords
daraxonrasib, RMC-6236, objective response rate, progression-free survival, overall survival
MeSH terms
Progression-Free Survival, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Mutation, Pancreatic Neoplasms, Piperazines, Genes, ras, Time Factors, ras Proteins, Carcinoma, Pancreatic Ductal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.